Rola dronedaronu we współczesnej terapii zaburzeń rytmu serca

Atrial fibrillation (AF) is one of the most common arrhythmia. Treatment of AF consists of rhythm control or rate control and prevention of thromboembolic events. For many years, conducted a study on the introduction of new, effective and safe anti-arrhythmic drugs, and therefore have high hopes associated with dronedarone. On the basis of DAFNE, EURIDIS, ADONIS and DIONYSOS demonstrated that dronedarone is effective in maintaining normal sinus rhythm than placebo and less effective than amiodarone. At the same time it was noted that the chronic use of dronedarone is associated with fewer side effects, and the same it is more acceptable drug than amiodarone. ANDROMEDA and PALLAS trial were terminated prematurely, its demonstrate restriction using of dronedarone. That why in 2012 guidelines of ESC was updated. Currently dronedarone is contraindicated in heart failure, and even in asymptomatic left ventricular systolic dysfunction. In ischemic heart disease, dronedarone has become a second- line drug, giving priority sotalol. Maintains the possibility of using dronedarone in non-severe structural heart disease and hypertension complicated by cardiac hypertrophy. Research on dronedarone showed that the drug is a poor competitor for other, older anti-arrhythmic drugs.